1

Obinutuzumab (GA101): A Comprehensive Overview

obinutuzumab099186
Obinutuzumab, referred to as GA101, represents an novel antibody designed to treat chronic lymphocytic leukemia. The medication targets CD20 expressed on B lymphocytes, resulting in ADCC and destruction. Clinical https://www.targetmol.com/compound/obinutuzumab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story